Skip Navigation LinksHome > March 1, 2004 - Volume 35 - Issue 3 > Renal Tubular Dysfunction Associated With Tenofovir Therapy:...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
Brief Report: Clinical Science

Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases

Peyrière, Hélène PharmD, PhD*; Reynes, Jacques MD, PhD†; Rouanet, Isabelle MD‡; Daniel, Nathalie MD§; de Boever, Corinne Merle MD†; Mauboussin, Jean-Marc MD‡; Leray, Hélène MD∥; Moachon, Laurence MD¶; Vincent, Denis MD, PhD‡; Salmon-Céron, Dominique MD, PhD§

Free Access
Article Outline
Collapse Box

Author Information

From the *Department of Medical Pharmacology, Lapeyronie Hospital, CHU Montpellier, Montpellier; Department of Nephrology, Lapeyronie Hospital, Montpellier; †Department of Infectious Diseases, Gui de Chauliac Hospital, CHU Montpellier, Montpellier; ‡Department of Internal Medicine A–Pneumology Department, Caremeau Hospital, Nîmes; and §Department of Internal Medicine and Infectious Diseases, and ¶Pharmacovigilance Center, Cochin Hospital, University Paris V, Paris, France.

Received for publication June 23, 2003; accepted November 24, 2003.

Reprints: Jacques Reynes, Department of Infectious Diseases, Gui de Chauliac Hospital, CHU Montpellier, F-34295 Montpellier, France (e-mail: j-reynes@chu-montpellier.fr).

Collapse Box

Abstract

We describe 7 cases of renal tubular injury in HIV-infected patients receiving an antiretroviral regimen containing tenofovir. Our patients (5 women and 2 men) developed renal tubular dysfunction, with hypophosphatemia, normoglycemic glycosuria, proteinuria, and decrease of creatinine clearance. The first biologic signs of renal toxicity were observed after duration of tenofovir treatment from 5 weeks to 16 months, and they resolved less than 4 months after discontinuation of tenofovir. Six patients had a low body weight (<60 kg). Five patients received low doses of ritonavir, and 1 received didanosine. In 5 patients, the signs resolved with the discontinuation of only the tenofovir. A renal biopsy performed in 1 patient was consistent with tubulointerstitial injury. Proximal tubulopathy appears to be a rare adverse effect of long-term tenofovir therapy. In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction.

Tenofovir (Viread; Gilead, Foster City, CA) is a nucleotide analogue used in the treatment of HIV infection. 1 Tenofovir is extensively excreted by the renal route by means of glomerular filtration and active tubular secretion. 2 This drug is structurally close to adefovir and cidofovir, which are used in the treatment of hepatitis B infection and cytomegalovirus infection, respectively. 1,3 High doses of adefovir and cidofovir have been involved in renal injuries. 4 Moreover, 2 cases of Fanconi syndrome have been previously reported with cidofovir. 5,6 Until now, few cases of Fanconi syndrome and acute renal failure have been described with tenofovir. 7–10 We report 7 new cases of renal tubular injury in patients treated with tenofovir.

Back to Top | Article Outline

PATIENTS

Case 1

A 48-year-old HIV-infected woman had been treated with ritonavir/lopinavir, lamivudine, efavirenz, and tenofovir since August 2001. In addition, the patient received fenofibrate and pravastatin for dyslipidemia. Before starting tenofovir, her serum creatinine level was normal. In March 2002, laboratory tests showed phosphatemia at 0.39 mmol/L, proteinuria at 1.7 g/L, glycosuria at 27.5 mmol/L, and serum creatinine level at 88 μmol/L. Glycemia, creatine kinase, and aminotransferase levels were normal. One week later, the patient complained of paresthesia in the lower back and legs, leading to the discontinuation of pravastatin and fenofibrate. The pain persisted, however, and 1 week later, biologic test results remained abnormal. At that time, the tenofovir plasma level was 380 ng/mL (15 hours after drug administration). Urinary protein electrophoresis showed albumin of 26.3%, α1-glycoprotein of 24.5%, α2-glycoprotein of 24.7%, β-microglobulin of 10.8%, and γ-globulin of 13.7%. Chromatography of urinary amino acid showed severe hyperaminoaciduria with citrullinuria, compatible with tubulopathy. All antiretroviral agents were stopped. Clinical symptoms disappeared within 1 week, and laboratory abnormalities returned to baseline values within 3 months.

Back to Top | Article Outline
Case 2

A 56-year-old HIV-infected woman had been treated with ritonavir/lopinavir, lamivudine, efavirenz, and tenofovir since May 2001. In addition, she received fenofibrate for dyslipidemia. Before starting tenofovir, her serum creatinine level was normal. In March 2002, the patient complained of pains in the legs and elbows. Laboratory tests showed phosphatemia at 0.72 mmol/L, proteinuria at 1.59 g/L, glycosuria at 7.7 mmol/L, and serum creatinine level at 78 μmol/L. Glycemia, creatine kinase, and aminotransferase levels were normal. Urinary protein electrophoresis showed albumin of 39.8%, α1-glycoprotein of 18.8%, β2-glycoprotein of 21.8%, β-microglobulin of 9%, and γ-globulin of 10.6%, compatible with renal tubulopathy. Only the tenofovir was stopped. The pains disappeared within 1 week, and laboratory abnormalities returned to baseline values within 3 months.

Back to Top | Article Outline
Case 3

A 49-year-old man had been treated with didanosine, lamivudine, ritonavir, amprenavir, and tenofovir since August 2001. Before starting tenofovir, his serum creatinine level was normal. In May 2002, laboratory tests showed phosphatemia at 0.41 mmol/L, proteinuria at 1.15 g/L, glycosuria at 0.8 mmol/L, and serum creatinine level at 101 μmol/L. Glycemia and aminotransferase levels were normal. Urinary protein electrophoresis showed albumin of 47.4%, α1-glycoprotein of 10%, α2-glycoprotein of 21.1%, β-microglobulin of 9.2%, and γ-globulin of 12.3%. Only the tenofovir was stopped. Within 3 months, laboratory abnormalities normalized.

Back to Top | Article Outline
Case 4

A 35-year-old HIV-infected woman, coinfected with hepatitis C virus (HCV), had been followed for Crohn disease since 1983. In May 2001, a new treatment combined abacavir, tenofovir, and ritonavir/lopinavir. When this tritherapy was started, the patient presented with persistent diarrhea related to her Crohn disease, her body weight was 38 kg, and her serum creatinine level was normal. With the new antiretroviral regimen, she presented a gain of body weight of 9 kg (47 kg). In April 2002, laboratory tests showed proteinuria at 1.86 g per 24 hours, glycosuria at 8.2 mmol/L, and serum creatinine level at 349 μmol/L. Only the tenofovir was stopped and replaced by lamivudine. Within 4 months, biologic parameters returned to normal values.

Back to Top | Article Outline
Case 5

A 42-year-old HIV-infected woman had been treated with abacavir, ritonavir/lopinavir, lamivudine, and tenofovir since November 2001. Before starting tenofovir, her serum creatinine level was normal. Since the start of tenofovir, phosphatemia progressively decreased to a value of 0.23 mmol/L in September 2002, which led to phosphorus supplementation. Concomitantly, neurologic symptoms related to HIV gradually worsened. In March 2003, laboratory tests showed proteinuria at 0.78 g/L, normoglycemic glycosuria at 19.2 mmol/L, and serum creatinine level at 135 μmol/L. Within 10 months, the body weight of the patient decreased to 38 kg. At that time, the tenofovir plasma level, measured 16 hours after administration, was 1159 ng/mL. Only the tenofovir was stopped. Within 3 months, laboratory abnormalities significantly improved, and a body weight gain of 11 kg was observed.

Back to Top | Article Outline
Case 6

A 41-year-old HIV-infected woman coinfected with HCV had received abacavir, nevirapine, and tenofovir since November 2001. Before starting tenofovir, her serum creatinine level was normal. In August 2002, the patient started treatment against HCV infection with ribavirin and pegylated (PEG)-interferon. In March 2003, the patient complained of paresthesia and myalgia in her lower limbs. Laboratory parameters showed phosphatemia at 0.51 mmol/L, proteinuria at 0.56 g/L, normoglycemic glycosuria at 0.3 mmol/L, and serum creatinine level at 84 μmol/L. In addition, anemia was observed with hemoglobinemia at 7.5 g/dL. Within 10 months, the body weight of the patient decreased to 40 kg. Urinary protein electrophoresis showed albumin of 29.1%, compatible with renal tubular injury. At that time, the tenofovir plasma level, measured 16 hours after administration, was 804 ng/mL. Only the tenofovir was stopped. Within 2 weeks, laboratory abnormalities normalized and a body weight gain of 4 kg was observed.

Back to Top | Article Outline
Case 7

A 57-year-old HIV-infected man had been treated with lamivudine, abacavir, and tenofovir since June 2003. Before starting tenofovir, the patient received atazanavir with the same nucleoside reverse transcriptase inhibitors (NRTIs) but stopped after 3 months because of hyperglycemia. His serum creatinine level was normal. The patient received metformin and glibenclamide for hyperglycemia, rilmenidine for hypertension, and cotrimoxazole for Pneumocystis prophylaxis. Five weeks after initiation of the tenofovir, the patient suddenly developed acute renal failure, with serum creatinine level at 376 μmol/L, proteinuria at 2.7 g/L, (6.2 g per 24 hours) and hematuria. Other laboratory tests showed phosphatemia at 0.57 mmol/L, metabolic acidosis, and normoglycemic glycosuria at 31 mmol/L. A renal biopsy revealed tubulointerstitial nephropathy with a primarily lymphocytic infiltrate. Glomeruli were normal. All drugs were discontinued. One month later, serum creatinine level was at 193 μmol/L, with persistent proteinuria and glycosuria. Within 3 months, laboratory abnormalities significantly improved.

Demographic data are reported in Table 1, and biologic data are summarized in Table 2.

Table 1
Table 1
Image Tools
Table 2
Table 2
Image Tools
Back to Top | Article Outline

DISCUSSION

We present 7 cases of renal injury associated with tenofovir therapy. Some renal disorders observed in our patients are consistent with Fanconi syndrome, including proximal renal tubular acidosis, normoglycemic glycosuria, hypophosphatemia, hypouricemia, hypokalemia, generalized aminoaciduria, and proteinuria. 11 In some cases, acute renal failure may be observed.

Tenofovir, like cidofovir and adefovir, is an acyclic nucleoside phosphonate. 4 The 3 drugs are excreted by glomerular filtration and active tubular secretion. In the proximal tubule, cidofovir and adefovir interact with more than 1 renal transporter. They enter the renal cells on human renal organic anion transporter 1 (hOATI) and exit on multidrug resistance-associated protein 2 (Mrp-2). 3,11 Cidofovir and high-dose adefovir have been previously involved in renal dysfunction, and hOAT1 seems to play an active role in nephrotoxicity associated with these drugs. 4,12 Although efficiently transported by hOAT1, tenofovir shows weak cytotoxicity in isolated human proximal tubular cells. 4,13 In addition, a recent study showed that tenofovir does not seem to interfere with mitochondrial function, as suggested previously in studies relating nephrotoxicity to adefovir. 14,15 Finally, in a clinical trial, the safety profile of tenofovir was reported to be similar to that of placebo. 16

Our 7 patients had been treated with tenofovir for 5 to 64 weeks when the first symptoms of renal dysfunction occurred. In all patients, laboratory abnormalities rapidly improved after stopping the tenofovir. It seems unlikely that other drugs were responsible for renal dysfunction, because in 5 patients, only the tenofovir was discontinued.

A median decrease in creatinine clearance of 46% (range: 20%–78%) was observed. At baseline, some patients presented a decrease in creatinine clearance (calculated with the formula of Cockroft and Gault), despite serum creatinine levels showing normal ranges (see Table 2). Six patients had a low body weight. With these lightweight patients, serum creatinine level seems a poor parameter by which to evaluate renal function, and we recommend systematically calculating creatinine clearance.

Pharmacokinetics of tenofovir in HIV-infected patients showed median steady-state peak concentrations of 326 ng/mL and a trough value of about 40 ng/mL. 1 Plasma levels of tenofovir were measured in 3 patients at the time of renal dysfunction. Results showed high values (ie, 380 ng/mL, 1159 ng/mL, and 804 ng/mL [about 16 hours after drug administration], respectively). In animal models, nephrotoxicity seems to be dose dependent. Thus, this dose dependence could be one of the potential mechanisms of tenofovir-related renal complications.

In recent publications, 4 cases of Fanconi syndrome, 2 cases of acute renal failure, and 1 case of nephrogenic insipidus diabetes have been reported. 7–10,17 The time lapse between initiation of tenofovir and the onset of renal abnormalities is variable: 4 to 7 weeks in some cases 8,9,17 and several months in others. 7,10

A renal biopsy was performed in some published cases and showed acute tubular necrosis with normal glomeruli. 7–10 In our cases, only 1 renal biopsy was performed in patient 7. Results were in accordance with data reported in the literature (ie, tubulointerstitial nephropathy with normal glomeruli). In this patient, conventional immunofluorescence with anti-immunoglobulin and anti-C3 antibodies was negative. Furthermore, mild “tubular” proteinuria and glycosuria observed in other cases were consistent with a tubular source rather than with a glomerular leak.

In 5 cases, ritonavir was associated with antiretroviral regimens. This drug has been previously involved in acute renal failure. 18 Moreover, coadministration of ritonavir and lopinavir is known to increase pharmacokinetic parameters of tenofovir (maximum concentration [Cmax], +31%; minimum concentration [Cmin], +29%; area under the curve [AUC], +34%). 19 Ritonavir has been shown to be a potent inhibitor of Mrp-2–mediated transport. 20 As shown for adefovir and cidofovir, we suggest that Mrp-2 transports tenofovir outside renal tubules. Inhibition of Mrp-2 by ritonavir in patients taking tenofovir could be an explanation of the tubular dysfunction observed.

One patient (no. 3) has taken didanosine associated with tenofovir. Didanosine alone may be nephrotoxic, because 1 case of Fanconi syndrome has been reported. 21 Pharmacokinetic data showed a significant increase of bioavailability of didanosine when it is taken with tenofovir. 22 A recent publication reports the case of an HIV-infected patient with chronic renal insufficiency who developed acute renal failure and severe lactic acidosis when tenofovir was added to his antiretroviral regimen, including didanosine. 17

All our patients were extensively pretreated with NRTIs, which are known to induce mitochondrial defects. Even if an in vitro study showed that tenofovir does not induce mitochondrial toxicity, we speculate that after several months of therapy, tenofovir could worsen latent tubular injury in patients with a mitochondrial defect caused by previous treatment with NRTIs.

According to data presented here, occurrence of renal toxicity seems to focus on patients (1) with low body weight or altered renal function (low creatinine clearance) at baseline, (2) extensively pretreated with NRTIs and/or all nephrotoxic drugs, or (3) receiving ritonavir.

In conclusion, intensive renal monitoring, including creatinine clearance, proteinuria, and glycosuria, is essential at baseline and during treatment with tenofovir. Risk factors of nephrotoxicity and pertinence of therapeutic drug monitoring of tenofovir should be evaluated in prospective safety studies.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors thank Gilbert Deray, MD (Hôpital Pitié-Salpétrière, Paris), for his helpful comments and Gilles Peytavin, PharmD (Hôpital Bichat, Paris), for the measurement of tenofovir plasma levels.

Back to Top | Article Outline

REFERENCES

1. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001; 45:2733–2739.

2. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy. 2003; 23:29–43.

3. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999; 36:127–143.

4. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001; 20:641–648.

5. Vittecoq D, Dumitrescu L, Beaufils H, et al. Fanconi syndrome associated with cidofovir therapy. Antimicrob Agents Chemother. 1997; 41:1846.

6. Purohit N, Durr J, Lopez R. Cidofovir induced Fanconi syndrome and nephrogenic diabetes insipidus. Am J Kidney Dis. 2002; 39:26.

7. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002; 40:1331–1333.

8. Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002; 324:342–344.

9. Créput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003; 17:935–937.

10. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003; 36:1070–1073.

11. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003; 41:292–309.

12. Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000; 11:383–393.

13. Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002; 54:37–45.

14. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001; 32:734–740.

15. Birkus G, Hitchcock MJ, Cihlar T, et al. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002; 46:716–723.

16. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-weeks, randomized, double-blind study. AIDS. 2002; 16:1257–1263.

17. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis. 2003; 36:1082–1085.

18. Deray G, Bochet M, Katlama C, et al. Néphrotoxicité du ritonavir. Presse Med. 1998; 27:1801–1803.

19. Kearney BP, Flaherty J, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects. Presented at the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, 2001.

20. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999; 56:383–389.

21. Crowther MA, Callaghan W, Hodsman AB, et al. Dideoxyinosine-associated nephrotoxicity. AIDS. 1993; 7:131–132.

22. Flaherty J, Kearney B, Wolf J, et al. Coadministration of tenofovir DF (TDF) and didanosine (ddI): a pharmacokinetic (PK) and safety evaluation [abstract I-1729]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001.

Cited By:

This article has been cited 105 time(s).

Internal Medicine
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial
Nishijima, T; Takano, M; Ishisaka, M; Komatsu, H; Gatanaga, H; Kikuchi, Y; Endo, T; Horiba, M; Kaneda, S; Uchiumi, H; Koibuchi, T; Naito, T; Yoshida, M; Tachikawa, N; Ueda, M; Yokomaku, Y; Fujii, T; Higasa, S; Takada, K; Yamamoto, M; Matsushita, S; Tateyama, M; Tanabe, Y; Mitsuya, H; Oka, S
Internal Medicine, 52(7): 735-744.
10.2169/internalmedicine.52.9155
CrossRef
AIDS Research and Therapy
Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua, AC; Llorin, RM; Lai, K; Cavailler, P; Law, HL
AIDS Research and Therapy, 9(): -.
ARTN 19
CrossRef
Hiv Clinical Trials
Serious renal impairment occurs rarely with use of tenofovir
Scott, JD; Wolfe, PR; Bolan, RK; Guyer, B
Hiv Clinical Trials, 7(2): 55-58.

Clinical Pharmacology & Therapeutics
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
Kiser, JJ; Carten, ML; Aquilante, CL; Anderson, PL; Wolfe, P; King, TM; Delahunty, T; Bushman, LR; Fletcher, CV
Clinical Pharmacology & Therapeutics, 83(2): 265-272.
10.1038/sj.clpt.6100269
CrossRef
Clinical Nephrology
Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction
Morelle, J; Labriola, L; Lambert, M; Cosyns, JP; Jouret, F; Jadoul, M
Clinical Nephrology, 71(5): 567-570.

Hiv Medicine
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy
Buchacz, K; Brooks, JT; Tong, T; Moorman, AC; Baker, RK; Holmberg, SD; Greenberg, A
Hiv Medicine, 7(7): 451-456.

Journal of General Internal Medicine
Acquired Fanconi's syndrome associated with tenofovir therapy
Mathew, G; Knaus, SJ
Journal of General Internal Medicine, 21(): C3-C5.
10.1111/j.1525-1497.2006.00518.x
CrossRef
Antiviral Therapy
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Oprovil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H
Antiviral Therapy, 12(8): 1165-1173.

Hautarzt
The side effects of antiretroviral therapy
Hartmann, M
Hautarzt, 57(): 969-974.
10.1007/s00105-006-1240-6
CrossRef
Expert Opinion on Drug Metabolism & Toxicology
Tenofovir disoproxil fumarate for the treatment of HIV infection
Pham, PA; Gallant, JE
Expert Opinion on Drug Metabolism & Toxicology, 2(3): 459-469.
10.1517/17425255.2.3.459
CrossRef
Thescientificworldjournal
Early onset of tenofovir-induced renal failure: Case report and review of the literature
Patel, SM; Zembower, TR; Palella, F; Kanwar, YS; Ahya, SN
Thescientificworldjournal, 7(): 1140-1148.
10.1100/tsw.2007.164
CrossRef
AIDS
Effect of tenofovir on renal glomerular and tubular function
Fux, CA; Christen, A; Zgraggen, S; Mohaupt, MG; Furrer, H
AIDS, 21(): 1483-1485.

Clinical Drug Investigation
Renal safety of tenofovir in HIV-infected children - A prospective, 96-week longitudinal study
Vigano, A; Zuccotti, GV; Martelli, L; Giacomet, V; Cafarelli, L; Borgonovo, S; Beretta, S; Rombola, G; Mora, S
Clinical Drug Investigation, 27(8): 573-581.

Expert Opinion on Drug Safety
Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
Harris, M
Expert Opinion on Drug Safety, 7(4): 389-400.
10.1517/14740330802211423
CrossRef
Qjm-An International Journal of Medicine
Renal function and mitochondrial cytopathy (MC): more questions than answers
Hall, AM; Unwin, RJ; Hanna, MG; Duchen, MR
Qjm-An International Journal of Medicine, 101(): 755-766.
10.1093/qjmed/hcn060
CrossRef
Clinical Infectious Diseases
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Rodriguez-Novoa, S; Labarga, P; Soriano, V; Egan, D; Albalater, M; Morello, J; Cuenca, L; Gonzalez-Pardo, G; Khoo, S; Back, D; Owen, A
Clinical Infectious Diseases, 48(): E108-E116.
10.1086/598507
CrossRef
Therapie
Assessment of renal abnormalities in 107 HIV patients treated with tenofovir
Lochet, P; Peyriere, H; Le Moing, V; Blayac, JP; Hansel, S; Reynes, J
Therapie, 60(2): 175-181.

Antimicrobial Agents and Chemotherapy
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
Van Rompay, KKA; Brignolo, LL; Meyer, DJ; Jerome, C; Tarara, R; Spinner, A; Hamilton, M; Hirst, LL; Bennett, DR; Canfield, DR; Dearman, TG; Von Morgenland, W; Allen, PC; Valverde, C; Castillo, AB; Martin, RB; Samii, VF; Bendele, R; Desjardins, J; Marthas, ML; Pedersen, NC; Bischofberger, N
Antimicrobial Agents and Chemotherapy, 48(5): 1469-1487.
10.1128/AAC.48.5.1469.1487.2004
CrossRef
Psychosomatics
Antiretrovirals, part II: Focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors)
Zapor, MJ; Cozza, KL; Wynn, GH; Wortmann, GW; Armstrong, SC
Psychosomatics, 45(6): 524-535.

Clinical Infectious Diseases
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment
Gallant, JE; Parish, MA; Keruly, JC; Moore, RD
Clinical Infectious Diseases, 40(8): 1194-1198.

AIDS Reviews
The impact of human genetic variation on HIV disease in the era of HAART
Brumme, ZL; Harrigan, PR
AIDS Reviews, 8(2): 78-87.

Antimicrobial Agents and Chemotherapy
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells
Vidal, F; Domingo, JC; Guallar, J; Saumoy, M; Cordobilla, B; de la Rosa, RS; Giralt, M; Alvarez, ML; Lopez-Dupla, M; Torres, F; Villarroya, F; Cihlar, T; Domingo, P
Antimicrobial Agents and Chemotherapy, 50(): 3824-3832.
10.1128/AAC.00437-06
CrossRef
Enfermedades Infecciosas Y Microbiologia Clinica
Assessment and management of kidney disease in the HIV-1-infected patient. A practical review
Domingo, P; Knobel, H; Gutierrez, F; Barril, G; Fulladosa, X
Enfermedades Infecciosas Y Microbiologia Clinica, 28(3): 185-198.
10.1016/j.eimc.2009.05.004
CrossRef
Hiv Clinical Trials
Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin
Sanchez-Conde, M; Gil, P; Sanchez-Somolinos, M; Gonzalez-Lahoz, J; Soriano, V
Hiv Clinical Trials, 6(5): 278-280.

Journal of Antimicrobial Chemotherapy
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort
Crespo, M; Ribera, E; Suarez-Lozano, I; Domingo, P; Pedrol, E; Lopez-Aldeguer, J; Munoz, A; Vilades, C; Sanchez, T; Viciana, P; Teira, R; Garcia-Alcalde, ML; Vergara, A; Lozano, F; Galindo, MJ; Cosin, J; Roca, B; Terron, A; Geijo, P; Vidal, F; Garrido, M
Journal of Antimicrobial Chemotherapy, 63(1): 189-196.
10.1093/jac/dkn450
CrossRef
AIDS Patient Care and Stds
Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study
Young, B; Buchacz, K; Moorman, A; Wood, KC; Brooks, JT
AIDS Patient Care and Stds, 23(8): 589-592.
10.1089/apc.2008.0232
CrossRef
Hiv Medicine
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy
Winston, A; Amin, J; Mallon, PWG; Marriott, D; Carr, A; Cooper, DA; Emery, S
Hiv Medicine, 7(2): 105-111.

Journal of Infectious Diseases
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity
Hulgan, T; Haas, DW
Journal of Infectious Diseases, 194(): 1471-1474.

AIDS
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir
Crane, HM; Kestenbaum, B; Harrington, RD; Kitahata, MM
AIDS, 21(): 1431-1439.

Drugs
Renal disease in patients with HIV infection - Epidemiology, pathogenesis and management
Fine, DM; Perazella, MA; Lucas, GM; Atta, MG
Drugs, 68(7): 963-980.

Osteoporosis International
Risk factors for decreased bone density and effects of HIV on bone in the elderly
Jones, S; Restrepo, D; Kasowitz, A; Korenstein, D; Wallenstein, S; Schneider, A; Keller, MJ
Osteoporosis International, 19(7): 913-918.
10.1007/s00198-007-0524-8
CrossRef
American Journal of Kidney Diseases
Subclinical Tubular Injury in HIV-Infected Individuals on Antiretroviral Therapy: A Cross-sectional Analysis
Hall, AM; Edwards, SG; Lapsley, M; Connolly, JO; Chetty, K; O'Farrell, S; Unwin, RJ; Williams, IG
American Journal of Kidney Diseases, 54(6): 1034-1042.
10.1053/j.ajkd.2009.07.012
CrossRef
Antiviral Therapy
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children
Vigano, A; Aldrovandi, GM; Giacomet, V; Merlo, M; Martelli, L; Beretta, S; Luraschi, P; Rombola, I; Mora, S
Antiviral Therapy, 10(8): 917-924.

Pediatric Nephrology
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir
Hussain, S; Khayat, A; Tolaymat, A; Rathore, MH
Pediatric Nephrology, 21(7): 1034-1036.
10.1007/s00467-006-0109-3
CrossRef
Current Medicinal Chemistry
Treating chronic hepatitis B: Today and tomorrow
Borgia, G; Gentile, I
Current Medicinal Chemistry, 13(): 2839-2855.

Acta Endocrinologica-Bucharest
Iatrogenic cushing's syndrome and polyuria-polydipsia in an HIV-infected patient treated with ritonavir
Sorni-Moreno, P; Ferrer-Garcia, JC; de Medrano, VAL
Acta Endocrinologica-Bucharest, 4(3): 355-357.

Hiv Medicine
Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy
Overton, ET; Nurutdinova, D; Freeman, J; Seyfried, W; Mondy, KE
Hiv Medicine, 10(6): 343-350.
10.1111/j.1468-1293.2009.00693.x
CrossRef
Clinical Infectious Diseases
Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions
Zimmermann, AE; Pizzoferrato, T; Bedford, J; Morris, A; Hoffman, R; Braden, G
Clinical Infectious Diseases, 42(2): 283-290.

Current Pharmaceutical Design
Current HIV treatment guidelines - An overview
Rathbun, RC; Lockhart, SM; Stephens, JR
Current Pharmaceutical Design, 12(9): 1045-1063.

Current Pharmaceutical Design
Understanding and avoiding antiretroviral adverse events
Shibuyama, S; Gevorkyan, A; Yoo, U; Tim, S; Dzhangiryan, K; Scott, JD
Current Pharmaceutical Design, 12(9): 1075-1090.

Clinical Journal of the American Society of Nephrology
Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists
Berns, JS; Kasbekar, N
Clinical Journal of the American Society of Nephrology, 1(1): 117-129.
10.2215/CJN.00370705
CrossRef
Journal of Antimicrobial Chemotherapy
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study
Guaraldi, G; Roverato, A; Giovanardi, C; Ravera, F; Squillace, N; Orlando, G; Cappelli, G; Esposito, R; Palella, F
Journal of Antimicrobial Chemotherapy, 63(2): 374-379.
10.1093/jac/dkn499
CrossRef
Pharmacogenomics
Pharmacogenetics of tenofovir treatment
Rodriguez-Novoa, S; Labarga, P; Soriano, V
Pharmacogenomics, 10(): 1675-1685.
10.2217/PGS.09.115
CrossRef
AIDS Research and Human Retroviruses
Urinary beta(2)-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil furnarate
Gatanaga, H; Tachikawa, N; Kikuchi, Y; Teruya, K; Genka, I; Honda, M; Tanuma, J; Yazaki, H; Ueda, A; Kimura, S; Oka, S
AIDS Research and Human Retroviruses, 22(8): 744-748.

Clinical Infectious Diseases
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy
Reid, A; Stoehr, W; Walker, AS; Williams, IG; Kityo, C; Hughes, P; Kambugu, A; Gilks, CF; Mugyenyi, P; Munderi, P; Hakim, J; Gibb, DM
Clinical Infectious Diseases, 46(8): 1271-1281.
10.1086/533468
CrossRef
Journal of Virology
A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy
Dinoso, JB; Rabi, SA; Blankson, JN; Gama, L; Mankowski, JL; Siliciano, RF; Zink, MC; Clements, JE
Journal of Virology, 83(): 9247-9257.
10.1128/JVI.00840-09
CrossRef
Clinical Infectious Diseases
Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
Gupta, SK; Eustace, JA; Winston, JA; Boydstun, II; Ahuja, TS; Rodriguez, RA; Tashima, KT; Roland, M; Franceschini, N; Palella, FJ; Lennox, JL; Klotman, PE; Nachman, SA; Hall, SD; Szczech, LA
Clinical Infectious Diseases, 40(): 1559-1585.

Hiv Medicine
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study
Antoniou, T; Raboud, JM; Chirhin, S; Yoong, D; Govan, V; Gough, K; Rachlis, A; Loutfy, MR
Hiv Medicine, 6(4): 284-290.

Pediatrics
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
Hazra, R; Gafni, RI; Maldarelli, F; Balis, FM; Tullio, AN; DeCarlo, E; Worrell, CJ; Steinberg, SM; Flaherty, J; Yale, K; Kearney, BP; Zeichner, SL
Pediatrics, 116(6): E846-E854.
10.1542/peds.2005-0975
CrossRef
Medicina Clinica
Antiretroviral treatment associated life-threatening adverse events
Moreno-Cuerda, VJ; Morales-Conejo, M; Rubio, R
Medicina Clinica, 126(): 744-749.

AIDS
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Nelson, MR; Katlama, C; Montaner, JS; Cooper, DA; Gazzard, B; Clotet, B; Lazzari, A; Schewe, K; Lange, J; Wyatt, C; Curtis, S; Chen, SS; Smith, S; Bischofberger, N; Rooney, JF
AIDS, 21(): 1273-1281.

Expert Opinion on Pharmacotherapy
Experience with tenofovir disoproxil fumarate for antiretroviral therapy
Stephan, C
Expert Opinion on Pharmacotherapy, 9(7): 1197-1209.
10.1517/14656560802012338
CrossRef
Hiv Medicine
Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients
Ravasi, G; Lauriola, M; Tinelli, C; Brandolini, M; Uglietti, A; Maserati, R
Hiv Medicine, 10(4): 219-228.
10.1111/j.1468-1293.2008.00673.x
CrossRef
Antimicrobial Agents and Chemotherapy
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy
Jullien, V; Treluyer, JM; Rey, E; Jaffray, P; Krivine, A; Moachon, L; Lillo-Le Louet, A; Lescoat, A; Dupin, N; Salmon, D; Pons, G; Urien, S
Antimicrobial Agents and Chemotherapy, 49(8): 3361-3366.
10.1128/AAC.49.8.3361-3366.2005
CrossRef
Clinical Infectious Diseases
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy
Roling, J; Schmid, H; Fischereder, M; Draenert, R; Goebel, FD
Clinical Infectious Diseases, 42(): 1488-1495.

Journal of Infection
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
Badiou, S; De Boever, CM; Terrier, N; Baillat, V; Cristol, JP; Reynes, J
Journal of Infection, 52(5): 335-338.
10.1016/j.jinf.2005.07.020
CrossRef
Hepatology
Tenofovir disoproxil fumarate: Role in hepatitis B treatment
Wong, SN; Lok, ASF
Hepatology, 44(2): 309-313.
10.1002/hep.21307
CrossRef
AIDS Reader
Renal safety of tenofovir disoproxil fumarate
Sax, PE; Gallant, JE; Klotman, PE
AIDS Reader, 17(2): 90-+.

Future Virology
Role of tenofovir in the treatment of chronic HBV infection
van Bommel, F; Berg, T
Future Virology, 3(3): 207-220.
10.2217/17460794.3.3.207
CrossRef
Nature Reviews Drug Discovery
Acyclic nucleoside phosphonates: A key class of antiviral drugs
De Clercq, E; Holy, A
Nature Reviews Drug Discovery, 4(): 928-940.
10.1038/nrd1877
CrossRef
Current Pharmaceutical Design
Limitations of current antiretroviral agents and opportunities for development
Jain, R; Clark, NM; Diaz-Linares, M; Grim, SA
Current Pharmaceutical Design, 12(9): 1065-1074.

Expert Opinion on Drug Safety
Cardiovascular & renal - Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection
Wyatt, CM; Klotman, PE
Expert Opinion on Drug Safety, 5(2): 275-287.
10.1517/14740338.5.2.275
CrossRef
AIDS
Hypokalemia in HIV patients on tenofovir
Cirino, CM; Kan, VL
AIDS, 20(): 1671-1673.

Antiviral Therapy
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir
Gerard, L; Chazallon, C; Taburet, AM; Girard, PM; Aboulker, JP; Piketty, C
Antiviral Therapy, 12(1): 31-39.

Virchows Archiv
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies
Schmid, S; Opravil, M; Moddel, M; Huber, M; Pfammatter, R; Keusch, G; Ambuhl, P; Wuthrich, RP; Moch, H; Varga, Z
Virchows Archiv, 450(6): 665-670.
10.1007/s00428-007-0418-3
CrossRef
Antiviral Therapy
Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors
Venhoff, N; Setzer, B; MelkaoUi, K; Walker, UA
Antiviral Therapy, 12(7): 1075-1085.

Seminars in Nephrology
Antiretroviral Nephrotoxicities
Atta, MG; Deray, G; Lucas, GM
Seminars in Nephrology, 28(6): 563-575.
10.1016/j.semnephrol.2008.08.009
CrossRef
Journal of Virology
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
Mehandru, S; Vcelar, B; Wrin, T; Stiegler, G; Joos, B; Mohri, H; Boden, D; Galovich, J; Tenner-Racz, M; Racz, P; Carrington, M; Petropoulos, C; Katinger, H; Markowitz, M
Journal of Virology, 81(): 11016-11031.
10.1128/JVI.01340-07
CrossRef
Journal of Infectious Diseases
Tenofovir nephrotoxicity: Focusing research questions and putting them into clinical context
Szczech, LA
Journal of Infectious Diseases, 197(1): 7-9.
10.1086/524091
CrossRef
AIDS Research and Human Retroviruses
Progressive Renal Tubular Dysfunction Associated with Long-Term Use of Tenofovir DF
Kinai, E; Hanabusa, H
AIDS Research and Human Retroviruses, 25(4): 387-394.
10.1089/aid.2008.0202
CrossRef
Hiv Medicine
Tenofovir-associated renal and bone toxicity
Woodward, CLN; Hall, AM; Williams, IG; Madge, S; Copas, A; Nair, D; Edwards, SG; Johnson, MA; Connolly, JO
Hiv Medicine, 10(8): 482-487.
10.1111/j.1468-1293.2009.00716.x
CrossRef
Journal of Infectious Diseases
Simian Immunodeficiency Virus-Infected Macaques Treated with Highly Active Antiretroviral Therapy Have Reduced Central Nervous System Viral Replication and Inflammation but Persistence of Viral DNA
Zink, MC; Brice, AK; Kelly, KM; Queen, SE; Gama, L; Li, M; Adams, RJ; Bartizal, C; Varrone, J; Rabi, SA; Graham, DR; Tarwater, PM; Mankowski, JL; Clements, JE
Journal of Infectious Diseases, 202(1): 161-170.
10.1086/653213
CrossRef
Drug Safety
Sex differences in antiretroviral therapy-associated intolerance and adverse events
Clark, R
Drug Safety, 28(): 1075-1083.

Nephrology Dialysis Transplantation
Prevalence of chronic kidney disease in Chinese HIV-infected patients
Cheung, CY; Wong, KM; Lee, MP; Liu, YL; Kwok, H; Chung, R; Chau, KF; Li, CK; Li, CS
Nephrology Dialysis Transplantation, 22(): 3186-3190.
10.1093/ndt/gfm350
CrossRef
European Journal of Pediatrics
Hypercalciuria is the main renal abnormality finding in Human Immunodeficiency Virus-infected children in Venezuela
Gonzalez, C; Ariceta, G; Langman, CB; Zibaoui, P; Escalona, L; Dominguez, LF; Rosas, MA
European Journal of Pediatrics, 167(5): 509-515.
10.1007/s00431-007-0538-4
CrossRef
Antiviral Therapy
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study
Fux, CA; Rauch, A; Simcock, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H
Antiviral Therapy, 13(8): 1077-1082.

AIDS Reader
Proximal Tubular Dysfunction Associated With Tenofovir and Didanosine Causing Fanconi Syndrome and Diabetes Insipidus: A Report of 3 Cases
Irizarry-Alvarado, JM; Dwyer, JR; Brumble, LM; Alvarez, S; Mendez, JC
AIDS Reader, 19(3): 114-121.

AIDS Reader
Tenofovir Nephrotoxicity-The Disconnect Between Clinical Trials and Real-World Practice
Atta, MG; Fine, DM
AIDS Reader, 19(3): 118-119.

Nephrologie & Therapeutique
Kidney diseases in HIV-infected patients
Tourret, J; Tostivint, I; Deray, G; Isnard-Bagnis, C
Nephrologie & Therapeutique, 5(6): 576-591.
10.1016/j.nephro.2009.02.007
CrossRef
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry
Le Saux, T; Chhun, S; Rey, E; Launay, O; Weiss, L; Viard, JP; Pons, G; Jullien, V
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 865(): 81-90.
10.1016/j.jchromb.2008.02.008
CrossRef
Pharmacotherapy
Tenofovir for the Treatment of Hepatitis B Virus
Jenh, AM; Thio, CL; Pham, PA
Pharmacotherapy, 29(): 1212-1227.

Drugs
Tenofovir disoproxil fumarate - A review of its use in the management of HIV infection
Lyseng-Williamson, KA; Reynolds, NA; Plosker, GL
Drugs, 65(3): 413-432.

Expert Opinion on Pharmacotherapy
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Goicoechea, M; Best, B
Expert Opinion on Pharmacotherapy, 8(3): 371-382.
10.1517/14656566.8.3.371
CrossRef
AIDS Patient Care and Stds
Kidney disease in the HIV-infected patient
Fine, DM; Atta, MG
AIDS Patient Care and Stds, 21(): 813-824.
10.1089/apc.2006.0210
CrossRef
Expert Opinion on Drug Safety
Tenofovir-induced kidney injury
Gitman, MD; Hirschwerk, D; Baskin, CH; Singhal, PC
Expert Opinion on Drug Safety, 6(2): 155-164.
10.1517/14740338.6.2.155
CrossRef
Plos One
Renal Function Declines More in Tenofovir-than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naive Patients with HIV Infection
Nishijima, T; Gatanaga, H; Komatsu, H; Tsukada, K; Shimbo, T; Aoki, T; Watanabe, K; Kinai, E; Honda, H; Tanuma, J; Yazaki, H; Honda, M; Teruya, K; Kikuchi, Y; Oka, S
Plos One, 7(1): -.
ARTN e29977
CrossRef
Transplant Infectious Disease
Efficacy of combined antiviral therapy with lamivudine and tenofovir in a liver transplanted girl with de novo hepatitis B virus infection
Tufano, M; Liccardo, D; Riva, S; Candusso, M; Torre, G; Iorio, R
Transplant Infectious Disease, 15(2): E81-E84.
10.1111/tid.12057
CrossRef
Journal of Biomedical Science
Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney
Abraham, P; Ramamoorthy, H; Isaac, B
Journal of Biomedical Science, 20(): -.
ARTN 61
CrossRef
Expert Opinion on Drug Safety
Renal toxicity associated with tenofovir use
Rodriguez-Novoa, S; Alvarez, E; Labarga, P; Soriano, V
Expert Opinion on Drug Safety, 9(4): 545-559.
10.1517/14740331003627458
CrossRef
Future Virology
Current assays for HIV-1 diagnostics and antiretroviral therapy monitoring: challenges and possibilities
To, SWC; Chen, JHK; Yam, WC
Future Virology, 8(4): 405-419.
10.2217/FVL.13.21
CrossRef
Pediatric Nephrology
Update on tenofovir toxicity in the kidney
Hall, AM
Pediatric Nephrology, 28(7): 1011-1023.
10.1007/s00467-012-2269-7
CrossRef
Plos One
Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial
Nishijima, T; Gatanaga, H; Shimbo, T; Komatsu, H; Endo, T; Horiba, M; Koga, M; Naito, T; Itoda, I; Tei, M; Fujii, T; Takada, K; Yamamoto, M; Miyakawa, T; Tanabe, Y; Mitsuya, H; Oka, S
Plos One, 8(8): -.
ARTN e73639
CrossRef
AIDS
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control study
Judd, A; Boyd, KL; Stöhr, W; Dunn, D; Butler, K; Lyall, H; Sharland, M; Shingadia, D; Riordan, A; Gibb, DM
AIDS, 24(4): 525-534.
10.1097/QAD.0b013e3283333680
PDF (645) | CrossRef
AIDS
Serum creatinine changes in HIV-seropositive patients receiving tenofovir
El Sahly, HM; Teeter, L; Zerai, T; Andrade, RA; Munoz, C; Nnabuife, C; Hunter, R
AIDS, 20(5): 786-787.
10.1097/01.aids.0000216386.60481.47
PDF (928) | CrossRef
AIDS
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
Labarga, P; Barreiro, P; Martin-Carbonero, L; Rodriguez-Novoa, S; Solera, C; Medrano, J; Rivas, P; Albalater, M; Blanco, F; Moreno, V; Vispo, E; Soriano, V
AIDS, 23(6): 689-696.
10.1097/QAD.0b013e3283262a64
PDF (131) | CrossRef
AIDS
Response to Blaas et al., ‘Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases’
Ranneberg, B; Mertenskoetter, T; Pearce, G
AIDS, 21(6): 783.
10.1097/QAD.0b013e3280b077a6
PDF (349) | CrossRef
AIDS
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
Soriano, V; Rodríguez-Nóvoa, S; Labarga, P; D'Avolio, A; Barreiro, P; Albalate, M; Vispo, E; Solera, C; Siccardi, M; Bonora, S; Di Perri, G
AIDS, 24(7): 1064-1066.
10.1097/QAD.0b013e32833202e2
PDF (301) | CrossRef
AIDS
Metabolic bone disease in HIV infection
Borderi, M; Gibellini, D; Vescini, F; De Crignis, E; Cimatti, L; Biagetti, C; Tampellini, L; Re, MC
AIDS, 23(11): 1297-1310.
10.1097/QAD.0b013e32832ce85a
PDF (272) | CrossRef
AIDS
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia
Mulenga, LB; Kruse, G; Lakhi, S; Cantrell, RA; Reid, SE; Zulu, I; Stringer, EM; Krishnasami, Z; Mwinga, A; Saag, MS; Stringer, JS; Chi, BH
AIDS, 22(14): 1821-1827.
10.1097/QAD.0b013e328307a051
PDF (279) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients
Horberg, M; Tang, B; Towner, W; Silverberg, M; Bersoff-Matcha, S; Hurley, L; Chang, J; Blank, J; Quesenberry, C; Klein, D
JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(1): 62-69.
10.1097/QAI.0b013e3181be6be2
PDF (256) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients
Fletcher, CV; Kiser, JJ; Aquilante, CL; Anderson, PL; King, TM; Carten, ML
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(3): 298-303.
10.1097/QAI.0b013e31815e7478
PDF (107) | CrossRef
JCR: Journal of Clinical Rheumatology
Bone Pain Due to Fractures Revealing Osteomalacia Related to Tenofovir-Induced Proximal Renal Tubular Dysfunction in a Human Immunodeficiency Virus-Infected Patient
Perrot, S; Aslangul, E; Szwebel, T; Caillat-Vigneron, N; Le Jeunne, C
JCR: Journal of Clinical Rheumatology, 15(2): 72-74.
10.1097/RHU.0b013e31819c20d8
PDF (241) | CrossRef
AIDS
Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate
Lacombe, K; Gozlan, J; Boelle, P; Serfaty, L; Zoulim, F; Valleron, A; Girard, P
AIDS, 19(9): 907-915.

PDF (156)
AIDS
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
van Vonderen, MG; Lips, P; van Agtmael, MA; Hassink, EA; Brinkman, K; Geerlings, SE; Sutinen, J; Ristola, M; Danner, SA; Reiss, P
AIDS, 23(11): 1367-1376.
10.1097/QAD.0b013e32832c4947
PDF (212) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Renal Safety of Tenofovir Disoproxil Fumarate in HIV-1 Treatment-experienced Patients with Adverse Events Related to Prior NRTI Use: Data from a Prospective, Observational, Multicenter Study
Moreno, S; Domingo, P; Palacios, R; Santos, J; Falcó, V; Murillas, J; Estrada, V; Ena, J; Alvarez, M; Recover Study Group,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(3): 385-387.
10.1097/01.qai.0000221690.54349.83
PDF (283) | CrossRef
Back to Top | Article Outline
Keywords:

tenofovir; tubular injury; nephropathy; HIV; Fanconi syndrome

© 2004 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.